Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
Addition of Affimed’s innate cell engager improves cytotoxicity of natural killer cells and CAR-NK cellsNK cells with ICE® show at least comparable anti-tumor cell efficacy to CAR-NK cells with...
Source: marketscreener.com